Results 151 to 160 of about 646,127 (297)

Metal‐Supramolecular Drug Delivery System Empowered Meningeal Lymphatic Vessels‐Bridged Intracranial‐Peripheral Dual Immune Modulation for Reversing Glioblastoma Immune Suppression

Advanced Science, EarlyView.
A novel metal‐supramolecular nanoplatform (FLM@VC) enables efficient brain delivery via meningeal lymphatic vessels (MLVs), bypassing the blood‐brain barrier (BBB) through subcutaneous administration. It reprograms tumor‐associated macrophages (TAMs) and remodels the MLVs to promote DC trafficking and CD8+ T cell activation.
Chenxi Zhang, Zhongsheng Xu, Xiaowen Xu, Zening Zhang, Ranran Luo, Pengchen Ren, Yingying Luo, Qiuchi Wu, Xinyu Liu, Guodong Liu, Xiaojing He, Yun Liu   +11 more
wiley   +1 more source

Inhibition of Alzheimer amyloid β aggregation by polyvalent trehalose

Science and Technology of Advanced Materials, 2008
A glycopolymer carrying trehalose was found to suppress the formation of amyloid fibrils from the amyloid β peptide (1–42) (Aβ), as evaluated by thioflavin T assay and atomic force microscopy.
Yoshiko Miura et al
doaj  

Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation

Advanced Science, EarlyView.
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng, Ge Zhu, Siyu Sun, Wenbo Yao, Yuning Zhang, Yong‐Guang Yang, Tianmeng Sun   +6 more
wiley   +1 more source

AI Guided Protein Design for Next‐Generation Autogenic Engineered Living Materials

Advanced Intelligent Systems, EarlyView.
Autogenic engineered living materials (ELMs) integrate biology and materials science to create self‐regenerating and self‐healing materials. This perspective highlights emerging strategies in protein engineering and AI‐guided de novo design to expand the capabilities of autogenic ELMs.
Hoda M. Hammad, Anna M. Duraj‐Thatte
wiley   +1 more source

In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences. [PDF]

Alzheimers Res Ther
Mueller A, Jovalekic A, Chapleau M, Seidel J, Ritter M, Bickel EM, Kiessling N, MacSweeney E, Stephens AW, Koglin N.   +9 more
europepmc   +1 more source

Amyloid Disease

International Journal of Clinical Practice, 1954
openaire   +2 more sources

Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake. [PDF]

J Prev Alzheimers Dis
Charil A, Nelson TM, Reilhac A, Devanarayan V, Dhadda S, Irizarry MC, Kramer LD, Reyderman L.   +7 more
europepmc   +1 more source

Enhanced Sensitivity of a Modified Quaking‐Induced Conversion Diagnostic Test for the Broad Detection of Sporadic and Inherited Prion Diseases: A Retrospective Study

Annals of Neurology, EarlyView.
Objective Quaking‐induced conversion (QuIC) tests, which detect prion‐seeding activity in cerebrospinal fluid (CSF), have markedly advanced the antemortem diagnosis of prion diseases such as Creutzfeldt‐Jakob disease (CJD). These tests provide high diagnostic accuracy and enable timely differentiation from other rapidly progressive neurodegenerative ...
Jennifer Myskiw, Rebecca Fox, Dominic M.S. Kielich, Lise Lamoureux, Melanie Leonhardt, Olivia Nykvist, Jessy A. Slota, Kristen Avery, Clark Phillipson, Kathy Frost, Sharon Simon, Brian S. Appleby, Ben A. Bailey‐Elkin, Stephanie A. Booth   +13 more
wiley   +1 more source

Longitudinal amyloid burden with combined [¹¹C]PiB and [¹⁸F]NAV4694 PET scans. [PDF]

Imaging Neurosci (Camb)
Bettcher B, McLachlan M, Zammit M, McVea A, DiFilippo AH, Murali D, Pirasteh A, Jonaitis E, Landhough R, Betthauser T, Johnson S, Christian BT.   +11 more
europepmc   +1 more source

When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ‐PET Centiloid 15, Mean Age of 66 Years

Annals of Neurology, EarlyView.
Objective Sporadic late‐onset Alzheimer's disease (AD) is characterized by a long pre‐clinical phase where amyloid‐beta (Aβ) and tau begin to accumulate in the brain. The primary objective was to determine the age at which AD starts by finding the average population age when both positron emission tomography (PET) Aβ (Aβ‐PET) and plasma Aβ42/40 become ...
Rodrigo Cánovas, Timothy Cox, Vincent Doré, Pierrick Bourgeat, Jurgen Fripp, Azadeh Feizpour, Rosita Shishegar, Christopher J. Fowler, Simon M. Laws, Tenielle Porter, Stephanie Rainey‐Smith, Leslie M. Shaw, Randall J. Bateman, Yan Li, Ovod Vitaliy, Michael W. Weiner, John C. Morris, Tammie L.S. Benzinger, Suzanne E. Schindler, Akinori Nakamura, Takeshi Iwatsubo, Takeshi Ikeuchi, Takashi Kato, Paul Maruff, Hamid R. Sohrabi, Christopher C. Rowe, Ralph N. Martins, Colin L. Masters, James D. Doecke, for the Alzheimer's Disease Neuroimaging Initiative   +29 more
wiley   +1 more source